Compositions containing delta-9-THC-amino acid esters and process of preparation
AssigneeThe University of Mississippi
InventorsMahmoud A. Elsohly, Waseem Gul, Michael A. Repka, Soumyajit Majumdar, Mohammad Khalid Ashfaq
Life of this patent
Estimating the term…
Abstract
Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.
Claims23
A topical ophthalmic formulation for effecting ocular bioavailability of Δ9-THC and reducing the intraocular pressure in the treatment of glaucoma comprising a therapeutically effective amount of at least one compound of Δ9-THC amino ester composition of the formula
- wherein R1 is natural amino acid residue, and salts thereof in an acceptable ophthalmic carrier;
- and wherein the Δ9-THC amino ester composition consists essentially of pure Δ9-THC amino ester, wherein the formulation consists essentially of lipid nanoparticles.
A topical ophthalmic formulation for effecting ocular bioavailability of Δ9-THC and reducing the intraocular pressure in the treatment of glaucoma comprising a therapeutically effective amount of at least one compound of a Δ9-THC amino ester composition of the formula
- wherein R1 and R2 are residues of natural amino acids, and salts thereof in an acceptable ophthalmic carrier wherein the Δ9-THC amino ester composition consists essentially of a pure Δ9-THC amino ester, wherein the formulation consists essentially of lipid nanoparticles.
A topical ophthalmic formulation for effecting ocular bioavailability of Δ9-THC and reducing the intraocular pressure in the treatment of glaucoma comprising a therapeutically effective amount of at least one compound of a Δ9-THC amino ester composition of the formula
- wherein R1, R2 and R3 are residues of natural amino acids, and salts thereof;
- in an acceptable ophthalmic carrier and wherein the Δ9-THC amino ester composition consists essentially of a pure Δ9-THC amino ester, wherein the formulation consists essentially of lipid nanoparticles.
A topical ophthalmic formulation for effecting ocular bioavailability of Δ9-THC and reducing the intraocular pressure in the treatment of glaucoma comprising a therapeutically effective amount of at least one compound of Δ9-THC amino ester composition of the formula
- where A is a residue of 1, 2 or 3 natural amino acids, and salts thereof;
- in an acceptable ophthalmic carrier and wherein the Δ9-THC amino ester composition consists essentially of a pure Δ9-THC amino ester, wherein the formulation consists essentially of lipid nanoparticles.
Dependencies are inferred from the claim text.